en · de · es · pt
cardarine-notes.peptides6823.com › Topic › Cardarine As Investigational Pparδ Agonist — Field Notes

Cardarine As Investigational Pparδ Agonist — Field Notes

By Editorial Desk · published 2025-08-28 · last reviewed 2025-10-14 · Topic

The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-10-14 and is reviewed periodically as new material appears.

Cardarine as Investigational PPARδ Agonist

Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.

Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.

The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.

Detection, Regulation, and Quality Context

Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Cardarine at a glance

PropertyValueNotes
Common synonymsGW501516, GW-501516, GW 501516, endurobolNames vary in research and anti-doping documents.
Chemical classSynthetic PPARδ agonistSmall-molecule nuclear receptor ligand.
CAS Registry Number317318-70-0Identifier commonly associated with GW501516.
AppearanceWhite to off-white powderTypical for purified research material.
SolubilityLow in water; soluble in DMSO and ethanolOrganic solvents are common for laboratory stock solutions.

Background and Research Context

In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.

Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.

Related pages on this site

Mechanism and Research Context

In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.

GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.

Supporting material

== Disorders == Hyperactivity of theca cells causes hyperandrogenism, and hypoactivity leads to a lack of estrogen. Granulosa cell tumors, while rare (less than 5% of ovarian cancers), may occur in both granulosa cells and theca cells. Thecomas are benign proliferations of theca cells that may present with hormonal dysfunction. Dysfunction in theca cells is one of the leading cause of endocrine-based infertility, as either hyperactivity or hypoactivity of the theca cells can lead to fertility problems.

==== Ketamine ==== Research on the antidepressant effects of ketamine infusions at subanaesthetic doses has consistently shown rapid (4 to 72 hours) responses from single doses, with substantial improvement in mood in the majority of patients and remission in some. However, these effects are often short-lived, and attempts to prolong the antidepressant effect with repeated doses and extended ("maintenance") treatment have resulted in only modest success. A nasal spray formulation of esketamine, sold under the brand name Spravato, gained FDA approval in 2019 for the treatment of treatment-resistant depression when combined with an oral antidepressant. Evidence-based meta-analyses support treatment protocols that differ substantially from standard real-world clinical practice: an optimized dose of 0.71 mg/kg rather than the conventional 0.5 mg/kg, intravenous infusion rather than intranasal delivery, and a racemic formulation rather than esketamine alone.

In practice, the USSR was a highly centralised entity from its creation in 1922 until the mid-1980s when political forces unleashed by reforms undertaken by Mikhail Gorbachev resulted in the loosening of central control and its ultimate dissolution. Under the constitution adopted in 1936 and modified along the way until October 1977, the political foundation of the Soviet Union was formed by the Soviets (Councils) of People's Deputies. These existed at all levels of the administrative hierarchy with the Soviet Union as a whole under the nominal control of the Supreme Soviet of the USSR, located in Moscow within the Russian SFSR. Along with the state administrative hierarchy, there existed a parallel structure of party organizations, which allowed the Politburo to exercise large amounts of control over the republics. State administrative organs took direction from the parallel party organs, and appointments of all party and state officials required approval of the central organs of the party. Each republic had its own unique set of state symbols: a flag, a coat of arms, and, with the exception of Russia until 1990, an anthem. Every republic of the Soviet Union also was awarded with the Order of Lenin.

Class I: Severe deficiency (<10% activity) with chronic (nonspherocytic) hemolytic anemia Class II: Severe deficiency (<10% activity), with intermittent hemolysis Class III: Moderate deficiency (10–60% activity), hemolysis with stressors only Class IV: Non-deficient variant, no clinical sequelae Class V: Increased enzyme activity, no clinical sequelae

Sources: en.wikipedia.org

Supporting material

Two main trends impinge on the industry. On the supply side, biotechnology is rapidly gaining importance. In the synthesis of small molecule fine chemicals, the use of biocatalysts and microbial fermentation enable both a more sustainable and economic production than conventional organic chemistry. In the synthesis of big molecules, such as biopharmaceuticals, it is the method of choice. Biopharmaceuticals are expected to grow 15% per year, three times as fast as small molecule drugs. Five of the top ten drugs were biopharmaceuticals in 2010 (see table 6), and this is expected to grow to eight by 2016 (see table 2). On the demand side, the main customer base for fine chemicals, the pharmaceutical industry, is faced with slower growth of demand, patent expirations of many lucrative blockbuster drugs and stalling new product launches. In order to restrain these challenges, the leading companies are implementing restructuring programs, including a reduction of in-house chemical manufacturing and plant eliminations. Outsourcing is moving from a purely opportunistic to a strategic approach. It is difficult to judge whether the positive or negative effects of these initiatives will prevail. In a worst-case scenario, a condition could develop whereby even top-tier mid-sized, family-owned fine-chemical companies with state-of-the-art plants and processes could be relegated to producing small quantities of fine chemicals for new life-science products in late stage of development. In agro fine chemicals, the active ingredients are become more sophisticated and better performing.

There have been calls for tapentadol to be only marketed in countries where appropriate controls exist, but after performing a critical review, the United Nations Expert Committee on Drug Dependence in 2014 advised that tapentadol not be placed under international control but remain under surveillance. As mentioned, the enhanced potency of tapentadol makes it considerably more susceptible to abuse compared to other opioids. This increased potency is one of the key factors that contribute to its higher potential for misuse. Furthermore, tapentadol is water soluble, which allows for a variety of methods to ingest or administer the drug. It can be snorted, inhaled, or even delivered rectally, all of which significantly increase the risk of abuse and the potential for dangerous consequences. These factors combined make tapentadol a particularly risky substance when it comes to misuse, posing serious concerns for both individuals and public health. The FDA's Controlled Substance Staff (CSS) recognizes that tapentadol is available as an immediate-release formula, and that in the past there was no requirement of a medication guide for immediate-release opioids. However, tapentadol exhibits several distinctive properties that makes it highly abusable. According to them:

They granted accelerated approval to pembrolizumab as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma ("regardless of PD-L1 staining") following progression on a platinum-based chemotherapy, based on objective response rates (ORR) in the phase Ib KEYNOTE-012 study in August of the same year. In October 2016, the US FDA approved pembrolizumab for the treatment of people with metastatic non-small cell lung cancer whose tumors express PD-L1 as determined by an FDA-approved test. In May 2017, pembrolizumab received an accelerated approval from the US FDA for use in any unresectable or metastatic solid tumor with DNA mismatch repair deficiencies or a microsatellite instability-high state (or, in the case of colon cancer, tumors that have progressed following chemotherapy). This approval marked the first instance in which the FDA approved marketing of a drug based only on the presence of a genetic mutation, with no limitation on the site of the cancer or the kind of tissue in which it originated. The approval was based on a clinical trial of 149 participants with microsatellite instability-high or mismatch repair deficient cancers who enrolled on one of five single-arm trials. Ninety participants had colorectal cancer, and 59 participants had one of 14 other cancer types. The objective response rate for all participants was 39.6%. Response rates were similar across all cancer types, including 36% in colorectal cancer and 46% across the other tumor types. Notably, there were 11 complete responses, with the remainder partial responses.

== Mechanism of action == Ethacrynic acid acts by inhibiting NKCC2 in the thick ascending loop of Henle and the macula densa. Loss of potassium ions is less marked but chances of hypochloremic alkalosis are greater. The dose response curve of ethacrynic acid is steeper than that of furosemide and, in general, it is less manageable; dose range is 50–150 mg. Ethacrynic acid and its glutathione-adduct are potent inhibitors of glutathione S-transferase family members, which are enzymes involved in xenobiotic metabolism. This family of enzymes has been shown to have a high rate of genetic variability.

This reflected a new PLAN tactic of laying anti-personnel mines parallel to their anti-tank mines to kill policemen or soldiers either engaging in preliminary mine detection or inspecting the scene of a previous blast. In 1972, South Africa acknowledged that two more policemen had died and another three had been injured as a result of mines. The proliferation of mines in the Caprivi and other rural areas posed a serious concern to the South African government, as they were relatively easy for a PLAN cadre to conceal and plant with minimal chance of detection. Sweeping the roads for mines with hand held mine detectors was possible, but too slow and tedious to be a practical means of ensuring swift police movement or keeping routes open for civilian use. The SADF possessed some mine clearance equipment, including flails and ploughs mounted on tanks, but these were not considered practical either. The sheer distances of road vulnerable to PLAN sappers every day was simply too vast for daily detection and clearance efforts. For the SADF and the police, the only other viable option was the adoption of armoured personnel carriers with mine-proof hulls that could move quickly on roads with little risk to their passengers even if a mine was encountered. This would evolve into a new class of military vehicle, the mine resistant and ambush protected vehicle (MRAP). By the end of 1972, the South African police were carrying out most of their patrols in the Caprivi Strip with mineproofed vehicles.

Sources: en.wikipedia.org

Notes from published material

== Nomenclature == Various fairly standardized abbreviations for vaccine names have developed, although the standardization is by no means centralized or global. For example, the vaccine names used in the United States have well-established abbreviations that are also widely known and used elsewhere. An extensive list of them provided in a sortable table and freely accessible is available at a US Centers for Disease Control and Prevention web page. The page explains that "The abbreviations [in] this table (Column 3) were standardized jointly by staff of the Centers for Disease Control and Prevention, ACIP Work Groups, the editor of the Morbidity and Mortality Weekly Report (MMWR), the editor of Epidemiology and Prevention of Vaccine-Preventable Diseases (the Pink Book), ACIP members, and liaison organizations to the ACIP." Some examples are "DTaP" for diphtheria and tetanus toxoids and acellular pertussis vaccine, "DT" for diphtheria and tetanus toxoids, and "Td" for tetanus and diphtheria toxoids. At its page on tetanus vaccination, the CDC further explains that "Upper-case letters in these abbreviations denote full-strength doses of diphtheria (D) and tetanus (T) toxoids and pertussis (P) vaccine. Lower-case "d" and "p" denote reduced doses of diphtheria and pertussis used in the adolescent/adult-formulations.

== Ionization mechanisms == The photoionization mechanism is simplified under vacuum conditions: photon absorption by the analyte molecule, leading to electron ejection, forming a molecular radical cation, M•+. This process is similar to electron ionization common to GC/MS, except that the ionization process is soft, i.e., less fragmentation. In the atmospheric region of an LC/MS system, the ionization mechanism becomes more complex. The unpredictable fate of ions is generally detrimental to LC/MS analysis, but like most processes, once they are better understood, these properties can be exploited to enhance performance. For example, the role of dopant in APPI, first developed and patented for the atmospheric ion source of ion mobility spectrometry (IMS), was adapted to APPI for LC/MS. The basic APPI mechanisms can be summarized by the following scheme: Direct positive ion APPI

=== Sales === The Valve Index headset, controllers, and base stations sold out in the US, Canada, and Europe within a week of the Alyx announcement. By mid-January 2020, they were sold out in all 31 regions. According to Superdata, Valve sold 103,000 Index units in the fourth quarter of 2019 as a result of the Alyx announcements, compared to the total 149,000 sold throughout 2019, and the Index was the highest-selling VR headset for PCs during that quarter. Though Valve had expected to supply several Index orders in time for the release of Alyx, the COVID-19 pandemic limited their supply chain. Valve's Greg Coomer said Valve knew many people would not play Alyx on launch and that its audience was "relatively small right now". Newell described it as a "forward investment" into long-term technologies. In 2021, PCGamesN wrote that though it was "artfully crafted", Alyx had had little cultural impact. As of December 2024, Alyx had sold more than two million copies.

=== Naturally occurring isotope variation === Natural processes result in broad variations in the D/H ratio (DHR) in different pools of hydrogen. KIEs and physical changes such as precipitation and evaporation lead to these observed variations. Seawater varies slightly, between 0 and −10 per mil, while atmospheric water can vary between about −200‰ to +100‰. Biomolecules synthesized by organisms, retain some of the D/H signature of the water which they were grown on, plus a large fractionation factor which can be as great as several hundred ‰. Large D/H differences, of thousands of ‰, can be found between Earth and other planetary bodies such as Mars, likely due to variations in isotope fractionation during planet formation and the loss of hydrogen into space.

The Cortes also passed the Habeas corpus law, the freedom of assembly law, the foreigners law and the Trade Union Freedom law. The most controversial was the abortion law, passed in the spring of 1985, and which provoked the mobilization of Catholic sectors in defense of the "right to life". Alianza Popular appealed it before the Constitutional Court, but the latter ruled in favor of it. Also controversial and the subject of an appeal before the Constitutional Court was the modification of the system of election of the members of the General Council of the Judiciary contained in the Organic Law of the Judiciary, but again the court ruled in favor of the law. As for the "regional issue", in addition to the approval of the few remaining autonomy statutes, an enormous decentralization of public spending took place, with the transfer to the autonomous communities of the powers determined by their respective statutes. By 1988, the average expenditure of the autonomous communities had already reached 20% of total public spending, and since then it has continued to increase. However, both the government of the Basque Country, presided since 1984 by "peneuvist" José Antonio Ardanza and that of Catalonia, presided since 1980 by the leader of CiU Jordi Pujol, continued to demand greater levels of self-government and opposed the "leveling" of all the autonomous communities, also accusing the government of curtailing their competences by resorting to organic laws.

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine?

Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.

Is cardarine a steroid?

No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.

Why was cardarine not developed further?

Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.

How is cardarine detected in anti-doping tests?

Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.

Network